The Global Nonalcoholic Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,119.8 million in 2017 (based on existing approved therapies including anti-diabetics, vitamins, dietary supplements, and others) and is projected to exhibit a CAGR of 42.7% over the forecast period (2018 - 2026), as highlighted in a new report published by Coherent Market Insights.
Nonalcoholic fatty liver disease (NAFLD) is a condition which occur due to the presence of fat in more than 5% of liver cells. NAFLD affects people who consume little or no alcohol. According to the Harvard Medical School, January 2018 report, NAFLD is the most common liver disease and affects nearly 25% of American adults, 60% of whom were men. It increases the risk of heart disease and if left untreated, it can lead to nonalcoholic steatohepatitis (NASH), a condition causing inflamed liver. More than 40% of people with NAFLD develop NASH which can lead to scarring of the liver. Severe liver scarring, known as cirrhosis, increases the risk of liver cancer.
The most widely used treatment for NASH is to eliminate potential causes and risk factors such as weight loss and treatment for hyperglycemia or dyslipidemia. A study published by the National Center for Biotechnology Information in 2015, suggests that thiazolidinediones and vitamin E can help correct biochemical and histologic abnormalities in NASH.
Moreover, no medicines have been approved to treat NASH so far. However, researchers are developing medicines to improve the conditions. According to the National Institute of Diabetes and Digestive and Kidney Diseases, some studies suggest that pioglitazone (Actos), a medicine for type 2 diabetes, can improve NASH in people non-diabetic patients.
Companies in the market are focusing on extensive research to develop medicine for NASH treatment. For instance, in 2017, Gilead Sciences, Inc. announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase, in patients with nonalcoholic steatohepatitis.
Browse 26 Market Data Tables and 28 Figures spread through 187 Pages and in-depth TOC on "Nonalcoholic Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to nonalcoholic steatohepatitis treatment market, click the link below:
Key Takeaways of the Nonalcoholic Steatohepatitis Treatment Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.